Who is sponsoring NCT03518190?

NCT03518190 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT03518190?

Interventions in NCT03518190: Infrared spectroscopy (ODP).

What condition does NCT03518190 study?

NCT03518190 studies Pressure Ulcer Not Visible.

Is NCT03518190 still recruiting?

NCT03518190 is currently completed. Last updated 28 April 2022.

Last reviewed 2022-04-28 · How we verify

NCT03518190

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Detection of Pressure Induced Tissue Damage by Infrared Spectroscopy (ODP) Device

Completed NA Last updated 28 April 2022

What this trial tests

NA trial testing Infrared spectroscopy (ODP) in Pressure Ulcer Not Visible in 31 participants. Completed in 12 May 2021.

Timeline

30 July 2018

Primary endpoint
12 May 2021

12 May 2021

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	31
Start date	30 July 2018
Primary completion	12 May 2021
Estimated completion	12 May 2021
Sites	1 location across Israel

Drugs / interventions tested

Infrared spectroscopy (ODP)

Conditions studied

Pressure Ulcer Not Visible — all drugs for Pressure Ulcer Not Visible →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

18 and older, any sex, with Pressure Ulcer Not Visible. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to demonstrate that infrared spectroscopy is able to detect pressure injuries at a very early stage

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03518190 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 28 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03518190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing